膀胱癌治療與診斷市場－全球產業規模、佔有率、趨勢、機會與預測：治療、診斷、癌症類型、地區和競爭格局，2021-2031年

全球膀胱癌治療和診斷市場預計將從 2025 年的 4.5911 億美元大幅成長至 2031 年的 7.1171 億美元，複合年成長率為 7.58%。

該市場涵蓋了尿路上皮癌及相關癌症臨床治療中必不可少的各種藥物、免疫療法、外科手術和先進診斷檢測。推動市場擴張的關鍵因素包括全球人口老化以及吸菸和職業性接觸致癌性化學物質等風險因素的持續存在。美國癌症協會估計，到2025年，美國將新增84,870例膀胱癌病例，顯示在這一關鍵醫療領域，對有效篩檢和治療方法的需求迫在眉睫。然而，新型生物製藥和先進基因組診斷的高昂成本對市場構成了重大障礙。長期患者照護帶來的沉重經濟負擔以及新核准的查核點抑制劑的高昂價格嚴重限制了病患的用藥，尤其是在對價格敏感的開發中國家，最終阻礙了全球市場的永續成長和滲透。

市場促進因素

創新免疫療法和標靶治療的監管核准正在加速，從根本上改變了臨床格局，並成為市場擴張的主要驅動力。監管機構越來越優先批准具有先進作用機制的藥物，例如白細胞介素-15促效劑和查核點抑制劑，以滿足非肌肉層浸潤性和進行性尿路上皮癌領域尚未滿足的重大醫療需求。這種監管動能不僅擴大了可用的治療選擇，也顯著提升了近期核准治療方法的商業性前景。 2025年1月，Fierce Pharma公司報告稱，核准其近期核准的免疫療法藥物Anktiva到2028年銷售額將達到約9億美元。同時，抗體藥物複合體（ADC）在晚期治療方法中的應用日益廣泛，正在推動收入的快速成長，並刺激標準治療方案的重組。由於其在轉移性病灶治療中具有卓越的療效，臨床醫生越來越傾向於選擇基於抗體偶聯藥物（ADC）的聯合治療，尤其是恩福坦布-維多汀（enfortambu-vedotin），而非傳統化療。這項轉變也體現在全球領先的ADC產品強勁的市場表現。Astellas）報告稱，截至2025年4月，其產品PADCEV的全球銷售額達到1,641億日圓。此外，免疫腫瘤藥物持續推動整體市場成長，默克（Merck）報告稱，其產品Keytruda在2025年的季度銷售額將超過80億美元。這部分得益於市場對膀胱癌適應症的持續需求。

市場挑戰

新型生物製藥和先進基因組診斷的高昂成本是全球膀胱癌治療和診斷市場商業性擴張的主要障礙。儘管近期臨床創新展現出卓越的療效，但這些治療方法帶來的沉重經濟負擔顯著限制了患者的就醫和接受度。在許多醫療體系中，尤其是在對價格敏感的開發中國家，品牌查核點抑制劑的高昂價格往往導致支付方嚴格拒絕承保或要求患者自付高額費用。這種經濟障礙有效地限制了目標患者群體，阻礙了製藥公司充分發揮其產品組合的獲利潛力，並減緩了市場整體成長速度。近期產業數據顯示，這項經濟負擔的嚴重性不容忽視。根據美國臨床腫瘤學會（ASCO）的數據，到2025年，膀胱癌治療的年度調整後藥物治療費用將根據治療階段的不同，從10萬美元到超過50萬美元不等。如此高昂的價格造成了臨床應用與實際市場滲透率之間的差距。由於醫療機構在有限的預算內難以證明這些支出的合理性，先進治療方法的廣泛應用直接受到阻礙，從而限制了市場的有效擴張。

市場趨勢

對於對卡介苗（BCG）無反應的非肌肉層浸潤性膀胱癌，基因療法的出現為那些對傳統治療無效的患者提供了一個重要的膀胱保留替代方案。這一創新趨勢是利用非複製型腺病毒載體將干擾素-α基因直接遞送至尿路上皮，從而刺激持續的局部免疫反應。該治療方法滿足了那些已用盡標準膀胱內免疫療法且希望避免膀胱全切除術的患者的巨大未滿足需求，因此正獲得商業性上的成功。 2025年4月，《醫藥執行》（PharmExec）雜誌報道，其基因治療藥物Adstiradrine上市首年銷售額約7,900萬美元，顯示該藥物在泌尿系統領域具有很高的市場接受度。同時，新型膀胱內給藥系統的應用正在有效克服傳統液體輸注方法固有的藥物動力學限制。這些植入式裝置專為持續、可控制地輸送Gemcitabine等化療藥物而設計，確保藥物長期作用於腫瘤，並減少藥物在尿液中的快速排放。這種持續輸注平台的出現，透過在較長時間內維持治療濃度，改善了高風險疾病的臨床治療效果。例如，2025年4月，強生公司宣布其TAR-200膀胱內給藥系統在對卡介苗無反應的患者中取得了高達82.4%的完全緩解率，凸顯了這種創新給藥方法的卓越療效。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球膀胱癌治療與診斷市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 治療方法（化療、免疫療法、其他治療方法）
  • 診斷方法（膀胱鏡檢查、尿液檢查、其他診斷方法）
  • 按類型分類的癌症（移行細胞膀胱癌、鱗狀細胞膀胱癌和其他類型的癌症）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美膀胱癌治療與診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲膀胱癌治療與診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區膀胱癌治療與診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲膀胱癌治療和診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美膀胱癌治療與診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球膀胱癌治療與診斷市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Ameritech Diagnostic Reagent（Jiaxing）Co., Ltd
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline PLC
• Novartis International AG
• Pfizer Inc.
• Abbott Inc.
• Endo Pharmaceuticals Inc.
• Johnson & Johnson
• Merck & Co. Inc
• Astellas Pharma Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Bladder Cancer Therapeutics and Diagnostics Market is projected to expand considerably, growing from USD 459.11 Million in 2025 to USD 711.71 Million by 2031, reflecting a 7.58% Compound Annual Growth Rate. This market encompasses a comprehensive range of pharmaceutical agents, immunotherapies, surgical procedures, and advanced diagnostic tests vital for the clinical management of urothelial carcinoma and related cancers. Primary drivers of this market expansion include the increasing global geriatric population and the persistent presence of risk factors such as tobacco use and occupational exposure to carcinogenic chemicals. The American Cancer Society estimated 84,870 new bladder cancer diagnoses in the United States in 2025, underscoring the pressing demand for effective detection and treatment options within major healthcare sectors. However, the market faces a significant impediment due to the prohibitive costs associated with novel biologic therapies and advanced genomic diagnostics. The substantial economic burden of long-term patient care and the high price points of newly approved checkpoint inhibitors severely restrict patient access, particularly within price-sensitive developing economies, ultimately hindering the global market's scalable growth and broader adoption.

Market Driver

Accelerated regulatory approvals for innovative immunotherapies and targeted agents are fundamentally transforming the clinical landscape, serving as a key driver for market expansion. Regulatory bodies are increasingly prioritizing the authorization of advanced mechanisms, such as interleukin-15 superagonists and checkpoint inhibitors, to address significant unmet needs in both non-muscle-invasive and advanced urothelial carcinomas. This regulatory momentum not only broadens available treatment options but also fuels substantial commercial projections for recently sanctioned therapies, with Fierce Pharma reporting in January 2025 that the recently approved immunotherapy Anktiva is expected to generate nearly $900 million in sales by 2028. Concurrently, the growing use of Antibody-Drug Conjugates (ADCs) in advanced treatment regimens is driving rapid revenue growth and reshaping standard-of-care protocols. Clinicians are increasingly favoring ADC-based combinations, notably enfortumab vedotin, over traditional chemotherapy due to their superior efficacy in metastatic settings. This shift is evident in the robust financial performance of leading ADCs globally; Astellas Pharma Inc. reported in April 2025 that global sales of PADCEV rose to JPY 164.1 billion. Furthermore, immuno-oncology agents continue to underpin the broader market trajectory, with Merck reporting over $8 billion in quarterly sales for Keytruda in 2025, partly driven by sustained demand in bladder cancer indications.

Market Challenge

The prohibitive cost associated with novel biologic therapies and advanced genomic diagnostics poses a primary obstacle to the commercial expansion of the Global Bladder Cancer Therapeutics and Diagnostics Market. Despite the superior efficacy offered by recent clinical innovations, the significant financial burden of these regimens severely restricts patient access and adoption rates. In many healthcare systems, especially in price-sensitive developing economies or nations with limited reimbursement models, the high price of branded checkpoint inhibitors often leads payers to implement strict coverage denials or demand high co-payments. This economic barrier effectively limits the addressable patient population, preventing pharmaceutical companies from fully realizing the revenue potential of their portfolios and slowing the overall pace of market growth. The extent of this financial strain is highlighted by recent industry data. According to the American Society of Clinical Oncology in 2025, the adjusted yearly drug costs for bladder cancer care consistently ranged from $100,000 to over $500,000 per patient, depending on the treatment phase. Such elevated pricing creates a disparity between clinical availability and actual market uptake. As healthcare providers grapple with justifying these expenditures against constrained budgets, the widespread commercialization of advanced therapeutics is directly hampered, impeding the market's ability to scale effectively.

Market Trends

The emergence of gene therapy options for BCG-unresponsive non-muscle invasive bladder cancer is establishing a crucial bladder-preserving alternative for patients who have not responded to previous treatments. This innovative trend involves using non-replicating adenoviral vectors to deliver interferon-alpha genes directly into the urothelium, thereby stimulating a durable local immune response. This modality is gaining commercial traction by addressing critical unmet needs in patients who have exhausted standard intravesical immunotherapies and wish to avoid cystectomy, with PharmExec reporting in April 2025 that the gene therapy Adstiladrin generated approximately $79 million in sales during its first full year, signaling strong market adoption within the urological community. Simultaneously, the adoption of novel intravesical drug delivery systems is effectively overcoming the pharmacokinetic limitations inherent in traditional liquid instillations. These indwelling devices are specifically engineered to provide a sustained, controlled release of chemotherapeutic agents, such as gemcitabine, ensuring prolonged tumor exposure and mitigating rapid drug washout during voiding. This shift towards continuous dosing platforms is enhancing clinical outcomes in high-risk disease management by maintaining therapeutic concentrations over extended periods. For instance, Johnson & Johnson announced in April 2025 that its TAR-200 intravesical delivery system demonstrated an impressive 82.4 percent complete response rate in BCG-unresponsive patients, highlighting the superior efficacy of this innovative delivery method.

Key Market Players

• Ameritech Diagnostic Reagent (Jiaxing)Co., Ltd
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline PLC
• Novartis International AG
• Pfizer Inc.
• Abbott Inc.
• Endo Pharmaceuticals Inc.
• Johnson & Johnson
• Merck & Co. Inc
• Astellas Pharma Inc.

Report Scope

In this report, the Global Bladder Cancer Therapeutics and Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Bladder Cancer Therapeutics and Diagnostics Market, By Therapeutics

• Chemotherapy
• Immunotherapy
• Other Therapeutics

Bladder Cancer Therapeutics and Diagnostics Market, By Diagnostics

• Cystoscopy
• Bladder Ultrasound
• Urinalysis
• Other Diagnostics

Bladder Cancer Therapeutics and Diagnostics Market, By Cancer Type

• Transitional Cell Bladder Cancer
• Squamous Cell Bladder Cancer
• Other Cancer Types

Bladder Cancer Therapeutics and Diagnostics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Bladder Cancer Therapeutics and Diagnostics Market.

Available Customizations:

Global Bladder Cancer Therapeutics and Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Bladder Cancer Therapeutics and Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Therapeutics (Chemotherapy, Immunotherapy, Other Therapeutics)
  • 5.2.2. By Diagnostics (Cystoscopy, Bladder Ultrasound, Urinalysis, Other Diagnostics)
  • 5.2.3. By Cancer Type (Transitional Cell Bladder Cancer, Squamous Cell Bladder Cancer, Other Cancer Types)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Bladder Cancer Therapeutics and Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapeutics
  • 6.2.2. By Diagnostics
  • 6.2.3. By Cancer Type
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Therapeutics
      • 6.3.1.2.2. By Diagnostics
      • 6.3.1.2.3. By Cancer Type
  • 6.3.2. Canada Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Therapeutics
      • 6.3.2.2.2. By Diagnostics
      • 6.3.2.2.3. By Cancer Type
  • 6.3.3. Mexico Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Therapeutics
      • 6.3.3.2.2. By Diagnostics
      • 6.3.3.2.3. By Cancer Type

7. Europe Bladder Cancer Therapeutics and Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapeutics
  • 7.2.2. By Diagnostics
  • 7.2.3. By Cancer Type
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapeutics
      • 7.3.1.2.2. By Diagnostics
      • 7.3.1.2.3. By Cancer Type
  • 7.3.2. France Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapeutics
      • 7.3.2.2.2. By Diagnostics
      • 7.3.2.2.3. By Cancer Type
  • 7.3.3. United Kingdom Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Therapeutics
      • 7.3.3.2.2. By Diagnostics
      • 7.3.3.2.3. By Cancer Type
  • 7.3.4. Italy Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Therapeutics
      • 7.3.4.2.2. By Diagnostics
      • 7.3.4.2.3. By Cancer Type
  • 7.3.5. Spain Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Therapeutics
      • 7.3.5.2.2. By Diagnostics
      • 7.3.5.2.3. By Cancer Type

8. Asia Pacific Bladder Cancer Therapeutics and Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapeutics
  • 8.2.2. By Diagnostics
  • 8.2.3. By Cancer Type
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapeutics
      • 8.3.1.2.2. By Diagnostics
      • 8.3.1.2.3. By Cancer Type
  • 8.3.2. India Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapeutics
      • 8.3.2.2.2. By Diagnostics
      • 8.3.2.2.3. By Cancer Type
  • 8.3.3. Japan Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapeutics
      • 8.3.3.2.2. By Diagnostics
      • 8.3.3.2.3. By Cancer Type
  • 8.3.4. South Korea Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Therapeutics
      • 8.3.4.2.2. By Diagnostics
      • 8.3.4.2.3. By Cancer Type
  • 8.3.5. Australia Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Therapeutics
      • 8.3.5.2.2. By Diagnostics
      • 8.3.5.2.3. By Cancer Type

9. Middle East & Africa Bladder Cancer Therapeutics and Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapeutics
  • 9.2.2. By Diagnostics
  • 9.2.3. By Cancer Type
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapeutics
      • 9.3.1.2.2. By Diagnostics
      • 9.3.1.2.3. By Cancer Type
  • 9.3.2. UAE Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapeutics
      • 9.3.2.2.2. By Diagnostics
      • 9.3.2.2.3. By Cancer Type
  • 9.3.3. South Africa Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Therapeutics
      • 9.3.3.2.2. By Diagnostics
      • 9.3.3.2.3. By Cancer Type

10. South America Bladder Cancer Therapeutics and Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Therapeutics
  • 10.2.2. By Diagnostics
  • 10.2.3. By Cancer Type
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Therapeutics
      • 10.3.1.2.2. By Diagnostics
      • 10.3.1.2.3. By Cancer Type
  • 10.3.2. Colombia Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Therapeutics
      • 10.3.2.2.2. By Diagnostics
      • 10.3.2.2.3. By Cancer Type
  • 10.3.3. Argentina Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Therapeutics
      • 10.3.3.2.2. By Diagnostics
      • 10.3.3.2.3. By Cancer Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Bladder Cancer Therapeutics and Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Ameritech Diagnostic Reagent (Jiaxing)Co., Ltd
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Bristol-Myers Squibb Company
• 15.3. Eli Lilly and Company
• 15.4. F. Hoffmann-La Roche Ltd
• 15.5. GlaxoSmithKline PLC
• 15.6. Novartis International AG
• 15.7. Pfizer Inc.
• 15.8. Abbott Inc.
• 15.9. Endo Pharmaceuticals Inc.
• 15.10. Johnson & Johnson
• 15.11. Merck & Co. Inc
• 15.12. Astellas Pharma Inc.

16. Strategic Recommendations

17. About Us & Disclaimer